Mediwound (NASDAQ:MDWD) issued its earnings results on Tuesday, May 21st. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01), Morningstar.com reports. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.60 million. Mediwound had a negative return on equity of 383.19% and a negative net margin of 18.43%.
Shares of Mediwound stock traded down $0.12 on Friday, reaching $3.75. 101,000 shares of the company’s stock were exchanged, compared to its average volume of 232,289. The stock has a market capitalization of $105.19 million, a price-to-earnings ratio of -7.65 and a beta of 0.80. Mediwound has a 52 week low of $3.61 and a 52 week high of $7.35. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.79 and a current ratio of 3.99.
Several institutional investors have recently made changes to their positions in the company. Oppenheimer & Co. Inc. increased its position in shares of Mediwound by 6.5% during the 1st quarter. Oppenheimer & Co. Inc. now owns 32,800 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 2,000 shares during the last quarter. Meitav Dash Investments Ltd. boosted its stake in Mediwound by 0.6% in the 1st quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock worth $2,993,000 after purchasing an additional 3,536 shares during the period. Sargent Investment Group LLC bought a new stake in shares of Mediwound during the 4th quarter valued at about $55,000. Morgan Stanley boosted its position in shares of Mediwound by 65.6% during the 1st quarter. Morgan Stanley now owns 36,584 shares of the biopharmaceutical company’s stock valued at $183,000 after acquiring an additional 14,489 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Mediwound by 73.5% during the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 16,840 shares during the last quarter. 30.78% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts have issued reports on the company. Zacks Investment Research cut Mediwound from a “buy” rating to a “hold” rating in a report on Wednesday, March 27th. Oppenheimer set a $15.00 price target on Mediwound and gave the stock a “buy” rating in a report on Monday, March 25th.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Further Reading: Recession
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.